The company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis (CF) and primary ciliary dyskinesia. ReCode is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing in target cells. Recently, ReCode announced a new round of financing co-led by Pfizer Ventures and EcoR1 Capital with participation from an investor syndicate . . .